Literature DB >> 25818301

DNAM-1 expression marks an alternative program of NK cell maturation.

Ludovic Martinet1, Lucas Ferrari De Andrade2, Camille Guillerey3, Jason S Lee4, Jing Liu3, Fernando Souza-Fonseca-Guimaraes3, Dana S Hutchinson5, Tatiana B Kolesnik6, Sandra E Nicholson6, Nicholas D Huntington6, Mark J Smyth7.   

Abstract

Natural killer (NK) cells comprise a heterogeneous population of cells important for pathogen defense and cancer surveillance. However, the functional significance of this diversity is not fully understood. Here, we demonstrate through transcriptional profiling and functional studies that the activating receptor DNAM-1 (CD226) identifies two distinct NK cell functional subsets: DNAM-1(+) and DNAM-1(-) NK cells. DNAM-1(+) NK cells produce high levels of inflammatory cytokines, have enhanced interleukin 15 signaling, and proliferate vigorously. By contrast, DNAM-1(-) NK cells that differentiate from DNAM-1(+) NK cells have greater expression of NK-cell-receptor-related genes and are higher producers of MIP1 chemokines. Collectively, our data reveal the existence of a functional program of NK cell maturation marked by DNAM-1 expression.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25818301     DOI: 10.1016/j.celrep.2015.03.006

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  37 in total

1.  Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions.

Authors:  Kimberley A Stannard; Sébastien Lemoine; Nigel J Waterhouse; Frank Vari; Lucienne Chatenoud; Maher K Gandhi; Ludovic Martinet; Mark J Smyth; Camille Guillerey
Journal:  Blood Adv       Date:  2019-06-11

2.  Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo.

Authors:  Ji Sung Kim; Bo Ram Shin; Hong Kyung Lee; Jae Hee Lee; Ki Hun Kim; Jeong Eun Choi; A Young Ji; Jin Tae Hong; Youngsoo Kim; Sang-Bae Han
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 3.  Diversification of human NK cells: Lessons from deep profiling.

Authors:  Aaron J Wilk; Catherine A Blish
Journal:  J Leukoc Biol       Date:  2018-01-19       Impact factor: 4.962

Review 4.  Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Trends Immunol       Date:  2018-01-31       Impact factor: 16.687

Review 5.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

6.  Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.

Authors:  Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

Review 7.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

Review 8.  Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.

Authors:  Peng Xiong; Hai-Wei Sang; Min Zhu
Journal:  Immunology       Date:  2015-09-28       Impact factor: 7.397

9.  CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:  Xian-Yang Li; Indrajit Das; Ailin Lepletier; Venkateswar Addala; Tobias Bald; Kimberley Stannard; Deborah Barkauskas; Jing Liu; Amelia Roman Aguilera; Kazuyoshi Takeda; Matthias Braun; Kyohei Nakamura; Sebastien Jacquelin; Steven W Lane; Michele Wl Teng; William C Dougall; Mark J Smyth
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 10.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.